JAM
DNLI icon

Jupiter Asset Management’s Denali Therapeutics DNLI Stock Holding History

Jupiter Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50,023
Closed -$2.25M – 539
2021
Q4 		$2.25M Hold
50,023
– – 0.02% 337
2021
Q3 		$2.52M Buy
+50,023
New +$2.82M 0.03% 322

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Jupiter Asset Management's DNLI Position: Q1 2022 in Review

Jupiter Asset Management sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 50,023 shares — an estimated $2.25M sold.

Jupiter Asset Management first reported a position in DNLI in Q3 2021 and held it in 2 quarters. The position peaked at $2.52M in Q3 2021. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

  • Jupiter Asset Management reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Jupiter Asset Management sold 50,023 Denali Therapeutics shares in Q1 2022, an estimated $2.25M.
  • Jupiter Asset Management first reported a position in Denali Therapeutics in Q3 2021 and held it in 2 quarters.
  • Jupiter Asset Management's Denali Therapeutics position peaked at $2.52M in Q3 2021.
  • 190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Jupiter Asset Management's 13F filing for Q1 2022, filed 11 May 2022.